Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. Post author:Sam Post published:December 18, 2017 Post category:BioPharma The FDA broke new ground today with a first-of-its-kind therapy for eye disease. Source: BioSpace You Might Also Like ESSA Pharma Provides Business Update And Announces Financial Results For The First Quarter Ended December 31, 2016 February 12, 2017 Daiichi Sankyo's Tumor Drug Meets Primary Endpoint in Late-Stage Study October 30, 2017 NOXXON Pharma AG Announces Prospectus Publication And Share Transfer To The Public Offering Compartment Of The Euronext Growth Market July 11, 2017
ESSA Pharma Provides Business Update And Announces Financial Results For The First Quarter Ended December 31, 2016 February 12, 2017
NOXXON Pharma AG Announces Prospectus Publication And Share Transfer To The Public Offering Compartment Of The Euronext Growth Market July 11, 2017
